The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.
April 26th 2024
The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacy Technician Credi...
2.0 Credits / HIV/AIDS
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacist Credit)
2.0 Credits / HIV/AIDS
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Daily Medication Pearl: Dronabinol (Syndros)
July 21st 2022Dronabinol (Syndros) is a cannabinoid indicated in adults for the treatment of: anorexia associated with weight loss in patients with AIDS and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Read More
CDC: HIV Testing, Diagnoses Dropped Significantly During the COVID-19 Pandemic
July 14th 2022In 2020, there was a 17% decrease in new HIV diagnoses and significant reductions in HIV testing in health care and non-health care settings, impeding the Ending the HIV Epidemic initiative to increase testing and reduce infections.
Read More
Daily Medication Pearl: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide)
May 25th 2022Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.
Read More
FDA Approves Cabenuva to Treat HIV in Adolescents 12 Years of Age or Older
March 30th 2022FDA approves expanded indication for the treatment of HIV-1 in virologically suppressed adolescents 12 years of age or older, who weigh at least 35 kg, and who are on a stable antiretroviral regimen, with no history of treatment failure or known or suspected resistance to either cabotegravir or rilpivirine.
Read More